Top Markets
#1 DogBull DogBull +73.77%
#2 Siren Siren +32.42%
#3 OriginTrail OriginTrail +12.53%
#4 龙虾 (Lobster) 龙虾 (Lobster) +10.57%
#5 Verus Coin Verus Coin +10.55%
#6 COTI COTI +9.09%
#7 Falcon Finance Falcon Finance +8.47%
#8 PulseChain PulseChain +6.82%
#9 Tutorial Tutorial +5.97%
#10 Xphere Xphere +5.70%
Coin of the day
DogBull DogBull
Settings
Language
ENGLISH
Currency
USD
Theme
Acrivon Therapeutics, Inc. Common Stock Acrivon Therapeutics, Inc. Common Stock

Acrivon Therapeutics, Inc. Common Stock

ACRV
Rank in Stocks #22054
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
Share Price
$2.23
Last synced: 2026-08-21
Market Cap
$95.23M
Change (1 day)
1.14%
Change (1 year)
63.60%
Country
US
Trade Acrivon Therapeutics, Inc. Common Stock (ACRV)

Category

Healthcare
Operating Margin for Acrivon Therapeutics, Inc. Common Stock (ACRV)
Operating Margin as of 2026 TTM: 0.00%
According to Acrivon Therapeutics, Inc. Common Stock latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for Acrivon Therapeutics, Inc. Common Stock from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
-149.01% -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.72% -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.